More recently, investigations were warranted to assess the role of ADAM17 inhibitors in autoimmune diseases since elevated expression and/or activation levels of ADAM17 were observed in biopsies of patients affected by autoimmune diseases such as IPF, Crohn’s disease, RA, and psoriasis [2,17,110,111]. This evidence concerns the gene ADAM17 and idiopathic pulmonary fibrosis.